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Abstract
Blockade of cell cycle re-entry in quiescent cancer cells is a strategy to prevent can-
cer progression and recurrence. We investigated the action and mode of action of 
CPF mixture (Coptis chinensis, Pinellia ternata and Fructus trichosanthis) in impeding 
a proliferative switch in quiescent lung cancer cells. The results indicated that CPF 
impeded cell cycle re-entry in quiescent lung cancer cells by reduction of FACT and 
c-MYC mRNA and protein levels, with concomitant decrease in H3K4 tri-methylation 
and RNA polymerase II occupancy at FACT and c-MYC promoter regions. Animals 
implanted with quiescent cancer cells that had been exposed to CPF had reduced 
tumour volume/weight. Thus, CPF suppresses proliferative switching through tran-
scriptional suppression of FACT and the c-MYC, providing a new insight into thera-
peutic target and intervention method in impeding cancer recurrence.
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1  | INTRODUC TION
With improvements in treatment, a growing list of cancers has be-
come chronic diseases. In 2016, there were 14 million cancer sur-
vivors in the United States alone but many of them could later die 
from cancer recurrence. According to GLOBOCAN 2018, global 
cancer deaths could reach 9.6 million in 2018.1 Hence, prevention 
of cancer recurrence is a major concern facing the growing popula-
tion of cancer survivors, given the reality that no secondary recur-
rence prevention method is available after completion of primary 
treatment.
G0 phase is a cellular state in which cells are in reversible cell 
cycle arrest. To multicellular organisms, the G0 state is necessary for 
development as cells at different stages of development lineage, in-
cluding stem cells, slow-cycling cells and differentiated mature cells, 
all adopt the G0 state temporally or spatially.
2,3 Cancer cells can 
also share the G0 state and are also known as dormant or quiescent 
cancer cells.4 Together with insufficient angiogenesis and immune 
surveillance, quiescent cancer cells are one mechanism explaining 
clinically observed cancer dormancy.4 The presence of dormant can-
cer cells is a two-edge sword. While it is beneficial to a multicellu-
lar organism for cancer cells with uncontrolled proliferation to be 
halted, the same cancer cells in quiescence can survive most chemo- 
and radiotherapy and may, with time, acquire additional mutations 
and gain metastatic potential as they re-enter the cell cycle.5 The 
therapeutic strategy of eliminating G0 cancer cells or promoting cell 
cycle re-entry by quiescent cancer cells is regarded as risky, as treat-
ment efficacy in the G0 phase is uncertain, and surviving cells may 
be selected out for more aggressive characteristics. Also, there is no 
assurance that antiproliferative drugs will be sufficiently effective to 
eliminate the reactivated G0 cancer cells.
5 Considering that prolifer-
ation of G0 cancer cells upon cell cycle re-entry can simply replace 
the eradicated cancer cells during primary treatment,6,7 the develop-
ment of a therapeutic strategy aimed at impeding cell cycle re-entry 
by quiescent cancer cells is of importance. A major prerequisite to be 
able to implement this strategy is to identify the therapeutic target 
responsible for the proliferative switch and to establish an effec-
tive and safe method capable of exerting action on the therapeutic 
target.
Our knowledge of the mechanisms underlying cell cycle re-entry 
from a G0 state is growing. Apart from cyclin-dependent kinase inhi-
bition,8 histone modification, RNA interference and autophagy are 
all implicated in the proliferative switch from quiescent state.3,9-13 
Facilitates Chromatin Transcription (FACT) is a member of histone 
chaperone family and consists of subunits of structure-specific 
recognition protein 1 (SSRP1) and suppressor of Ty homolog-16 
(SPT16). In the nucleosome, FACT facilitates the passage of DNA 
and RNA polymerase by temporal eviction of histones.14 FACT then 
promotes the deposition of histones to re-establish the nucleo-
some.14 However, against intuition, genetic silencing of the histone 
chaperones affects only about 2% of gene transcription and elonga-
tion in lung cancer cells.15 Also, FACT is aberrantly overexpressed 
in cancers of breast, lung, pancreas and brain.16,17 Recently, we 
have shown that FACT mRNA and protein levels oscillate between 
the quiescent and proliferative state, and FACT is necessary and 
sufficient in the proliferative switch of quiescent lung cancer cells 
through transcriptional regulation of c-MYC, which in turn influence 
cyclin-dependent kinase inhibitor p27 and its regulatory proteins 
such as SKP2.18
Ideally, in cancer patients who have completed intensive treat-
ment, sometimes with considerable toxicity, any subsequent treat-
ment should be not only effective but possess few side effects, 
especially if quiescent cancer cells are to be maintained in the G0 
phase for a considerable period. Based on the principles of effective 
therapy, minimal toxicity and economical use, as well as the notion 
of ‘an old drug for anew use’, we have investigated Chinese herbal 
medicines for preventing cell cycle re-entry of quiescent lung cancer 
cells. The ancient book ‘Treatise on Miscellaneous Diseases’ written 
by Zhang Zhongjing (AD 150-219) is the first known complete col-
lection of Chinese medicine prescriptions.19 Known as the ‘ancestral 
book’ in China, the prescriptions are respected as ‘Kampo’ (Han dy-
nasty prescriptions) in Northeast Asia and are still used in universi-
ties of Chinese medicine. CPF (Chinese name: Xiao-Xian-Xiong Tang) 
was first described in the ‘Treatise on Miscellaneous Diseases’ and 
consists of three herbs: Coptis chinensis, Pinellia ternata and Fructus 
trichosanthis (Figure S1A). Based on the HPLC results, of the 63 com-
pounds identified, 43 were from Coptis chinensis (Figure S1B,C and 
Table S1). According to the theory of traditional Chinese medicine, 
CPF is used for treating diseases of the respiratory system, including 
pneumonia, asthma and pulmonary fibrosis in China. Here, we pres-
ent evidence that CPF is able to impede the proliferative switch of 
quiescent lung cancer cells by transcriptional suppression of FACT 
and c-MYC genes.
2  | MATERIAL S AND METHODS
2.1 | Cell lines
The lung cancer cell lines A549 (Cat. #: CCL-185) and H1975 (Cat. 
#: CRL-1435) and normal bronchial epithelial cell lines 16HBE (Cat. 
#: CCL-2741) and BEAS-2B (Cat. #: CCL-9609) were obtained from 
Grant/Award Number: 16401970700; 
Shanghai Municipal Education Commission, 
Grant/Award Number: “Gao Yuan Gao 
Feng” Team; Shanghai Municipal Health 
Commission, Grant/Award Number: 
ZYKC201601020
K E Y W O R D S
c-MYC, G0 cell cycle re-entry, lung cancer, structure-specific recognition protein 1, suppressor 
of Ty homolog-16
     |  2231BI et al.
ATCC and grown in RPMI 1640 supplemented with 10% v/v foetal 
bovine serum (AusGeneX), penicillin (100 U/mL) and streptomycin 
(100 μg/mL). The cells were cultured at 37°C with 5% CO2/95% air.
2.2 | CPF preparation
CPF consists of Coptis chinensis, Pinellia ternata and Fructus trichosan-
this. All the herbs obtained from Huayu Pharmacy Company were 
certificated based on the authentication by Chinese Pharmacopoeia, 
heavy metal and pesticide residue standards. In a weight ratio of 3:6:10, 
CPF was boiled in six volumes of pure water for 60 minutes twice. The 
combined supernatants after filtration were vacuum-dried at 60°C and 
reconstituted in DMSO (500 mg/mL) as stock and kept in 4°C.
2.3 | Retroviral transduction and plasmid 
transfection
The mVenus-p27K−20 was provided by Dr Toshihiko Oki (The University 
of Tokyo, Japan). It was mixed with packaging plasmids as described18 
and transfected into 50% confluent HEK293T cells with a calcium 
phosphate precipitation method. The resulting lentiviral particles were 
used to infect A549 cells with 8 µg/mL polybrene. The infected cells 
with mVenus-p27K- construct were selected by 0.2 mg/mL puromy-
cin. The SPT16 (OHu22815D) and SSRP1 (OHu17195D) plasmid were 
obtained from GenScript Company and transfected into cells with 
Lipofectamine™ RNAiMAX (Invitrogen, Life Technologies).
2.4 | SYBR green assay
Quiescent A549 (10 000 cells/well) and H1975 (7000 cells/well) cells 
were seeded in 96-well plates. The same number of cells/well was 
kept as a baseline and stored at −80°C. After treatment, the medium 
was gently aspirated and replaced with 100 µL of lysis buffer as de-
scribed.18 The cells were then lysed in the dark for 2 hours with shak-
ing twice (5 min/each time). The frozen cells used as baselines were 
thawed at room temperature, lysed in the same buffer and transferred 
to the treatment plate. The fluorescence intensity of stained DNA was 
measured by a plate reader (FLUOstar Omega, BMG Labtech) with ex-
citation at 485/20 nm and emission at 528/20 nm. GI value = [(FI of 
control − FI of baseline) − (FI of treated − FI of baseline)]/(FI of con-
trol − FI of baseline)×100%. FI = fluorescence intensity.
2.5 | CCK-8 assay
16HBE (10 000 cells/well) and BEAS-2B (10 000 cells/well) were 
seeded in 96-well plates overnight before the CPF treatment. The 
CCK-8 reagent (Dojindo) was added into wells directly and measured 
by a plate reader (FLUOstar Omega, BMG Labtech) with the optical 
density (OD) at 450 nm. Survival rate (%) = ODtreated/ODcontrol × 100.
2.6 | Flow cytometry assay
To distinguish G0 and G1 cells, the cells incubated with Hoechst 
33258 and Pyronin Y21 were injected into Gallios flow cytometer 
(Beckman Coulter). To determine mVenus-p27K- fluorescence, the 
experimental cells were fixed with paraformaldehyde for 10 minutes 
at room temperature and washed with PBS prior to data acquisition 
using a flow cytometer (FACSCalibur II) equipped with CellQuest 
Pro software (BD Biosciences). Flow cytometry data were analysed 
using FlowJo software (version 10.0.8).
2.7 | Quantitative reverse transcription-PCR
Real-time PCR was performed as described previously.21 The cDNA 
generated from total RNA (iScript™ cDNA Synthesis Kit, Bio-Rad) 
was mixed with SYBR Green containing SensiMix™ Master Mix 
(Bioline). The reaction was subjected to a thermocycle at 95°C for 
10 minutes followed by 45 cycles at 95°C for 15 seconds, at 60°C for 
15 seconds and at 72°C for 15 seconds. The primer sequences are 
described in the supplementary information (Table S2).
2.8 | Immunoblotting
A549 and H1975 cells were treated in 6-well plates, and cell lysates 
were prepared as described ref.19. Primary antibodies against SPT16 
(Cat. #: 12191), SSRP1 (Cat. #: 13421) and p27 (Cat. #: 3686) were from 
Cell Signaling Technology; Antibodies against SKP2 (Cat. #: sc7164) 
and c-MYC (Cat. #: sc70469) were from Santa Cruz Biotechnology. 
GAPDH antibody (Cat. #: ab8245) was obtained from Abcam.
2.9 | Chromatin immunoprecipitation (ChIP)
ChIP analysis was conducted with immunoprecipitation assay kit (Cat 
#: 17-295, Merck) together with ChIP-grade rabbit anti-H3K4me3 
(Cat #: ab8580, Abcam) and anti-RNA polymerase II antibodies (Cat 
#: 664911, BioLegend) and isotype rabbit IgG (Cat #: sc-2027, Santa 
Cruz Biotechnology). Immunoprecipitated DNA was quantified by 
quantitative real-time PCR. See primer sequences in Table S3. ChIP 
assays were repeated thrice and calculated as fold enrichment rela-
tive to the control IgG and normalized by input DNA.
2.10 | Immunocytochemistry
Cells detached from culture flasks were fixed in 10% buffered forma-
lin solution, dehydrated and embedded in paraffin blocks. Selected 
samples were sectioned (5 mm thick) and stained with haematoxylin 
and eosin, Ki-67 (Abcam, ab92353), as described previously.22 The 
primary antibodies were used at 1:500 for Ki-67. The sections were 
finally mounted with DPX Mountant for histology analysis.
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2.11 | Imaging study
Nikon Ti-E spinning disc confocal live cell microscope with a 20 × ob-
jective lens was used for time-lapse imaging analysis of cells cultured 
in a 0.17-mm glass-bottom 6-well plate (MatTek). An image was ac-
quired every 15 minutes for 36 hours. Image acquisition and video 
conversion were performed with NIS-Elements (version 4.5).
2.12 | Chemical profiling of CPF extracts using LC-
MS/MS
Chemical profiling of CPF was performed on a Agilent 1290 LC 
System (Agilent Technologies) coupled with SCIEX TripleTOF 4600® 
quadrupole time-of-flight mass spectrometry (AB Sciex) equipped 
with a DuoSpray Source. Chromatographic separation was achieved 
on an Acquity UPLC® HSS T3 Column (2.1 × 100 mm i.d., 1.8 μm; 
Waters). The mobile phase consisted of water containing 0.1% 
formic acid (A) and acetonitrile (B). The following gradient condi-
tion was used: 0-3.0 minutes, 5% B; 3.0-7.0 minutes, 5% B–13% B; 
7.0-18.0 minutes, 13% B; 18.0-19.0 minutes, 13% B–15% B; 19.0-
26.0 minutes, 15% B; 26.0-30.0 minutes, 15% B–25% B; 30.0-
38.0 minutes, 25% B–65% B; 38.0-43.0 minutes, 65%-95% B; and 
43.0-45 minutes, 95% B. Column oven temperature was set at 30°C, 
while the flow rate was 0.3 mL/min. Ionization was conducted using 
an electrospray ionization (ESI) source. Data were collected under 
both positive and negative ion modes. The mass spectrometry was 
operated in full-scan TOF-MS (m/z 100-1500) and information-de-
pendent acquisition (IDA) MS/MS modes; the collision energy was 
40 ± 20 eV. Both ion source gas 1 and 2 were set 50 psi. Curtain 
gas was 35 psi. The temperature and ionspray voltage floating were 
500°C and 5000/-4500 V, respectively. Data recording and process-
ing were performed by Analyst Ver. 1.6 software (AB Sciex).
2.13 | Animals study
Male BALB/c nude mice (6 weeks old) and male ICR mice (4 weeks 
old) were maintained under specific pathogen-free conditions with 
constant temperature (23 ± 2°C) and controlled light (12-hour light: 
12-hour dark). To examine the effect of CPF on tumour growth, qui-
escent A549 cells were induced to re-enter the cell cycle by plating 
at a low density and treated either with CPF at GI90 or with DMSO 
for 6 hours. The cell viability in both groups was evaluated by trypan 
blue exclusion, and they were >95% in both groups. Together with 
proliferative A549 cells, the pre-treated cells, 1 × 107 cells in 0.2 mL 
PBS, were subcutaneously injected into the left flank of BALB/c 
nude mice. The mice were anaesthetized for determining the tumour 
volume and weight 16 days after cancer cell injection.
2.14 | Statistical analysis
The statistical software SPSS (version 18.0) was used for analysis. 
One-way ANOVA was used to determine the difference between 
individual groups of data. Multiple comparison test was used to de-
termine whether the difference between individual groups (P < .05) 
was significant.
3  | RESULTS
3.1 | CPF suppresses proliferative switch from G0 
state in lung cancer cells
As described previously,18 experimental quiescence was achieved by 
removing serum from culture media for 5 days in the lung cancer cell 
line H1975 or contact inhibition for 3 days in the lung cancer cell 
line A549. Cell cycle re-entry was rendered by replenishing serum 
in serum-deprived cells or replating the contact-inhibited cells at 
lower density. By comparing DNA content immediately before cell 
cycle re-entry (ie at quiescence), the release from quiescence led to 
a surge of DNA synthesis at 36 hours (Figure 1A). CPF treatment, 
which was introduced at the time when the cells were released from 
quiescence, suppressed DNA synthesis in a dose-dependent fash-
ion. The concentrations of CPF at which the cytostatic action (ie an-
tiproliferation) reached 50% (GI50) and 90% (GI90) were calculated 
(Table S4). The inhibitory effect of CPF at GI90 for 36 hours on pro-
liferative switch was verified by Ki-67 immunostaining (Figure 1B).
To determine the effect of CPF on cell cycle phase distribution, 
quiescent A549 and H1975 cells were induced to re-enter the cell 
cycle in the presence of CPF at GI90. The cells were harvested 
at 12-hour intervals and subjected to flow cytometric analysis. In 
comparison with control cells, there was a clear increase in the 
proportion of cells at G0/G1 and decrease in S and G2/M phase 
following CPF treatment at 24 hours following cell cycle re-entry 
F I G U R E  1   CPF suppresses proliferative switch from G0 state in lung cancer cells. A, CPF or DMSO was administered upon releasing 
from quiescence for 36 h. The treated two lung cancer cell lines together with the quiescent baseline cells were incubated with lysis buffer 
containing SYBR Green, and the DNA contents were measured. *P < .05 vs DMSO. B, The non-quiescent and quiescent cells and the cells 
treated with DMSO or CPF at GI90 upon cell cycle re-entry for 36 h were harvested for analysis of Ki-67 by immunocytochemical staining. 
No CI: no contact inhibition; 3d CI: contact inhibition for 3 d; RP36h DMSO: treatment of replated cells with DMSO; RP36h CPF: treatment 
of replated cells with CPF at GI90. FCS: no removal of foetal calf serum; 5d SW: serum withdrawal for 5 d; SR36h DMSO: treatment of 
serum-replenished cells with DMSO; SR36h CPF: treatment of serum-replenished cells with CPF at GI90. C, The non-quiescent cells, 
quiescent cells and cells after releasing from G0 at indicated time were stained with Hoechst 33258 and Pyronin Y. Representative images 
and quantification data after analysis of Hoechst 33258 alone or both Hoechst 33258 and Pyronin Y are shown. Data are expressed as the 
mean ± SD from three experiments. *P < .05 vs DMSO at each time-point. #P > .05 vs No CI or FCS
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(Figure 1C). Since cells at G0 and G1 are both diploid, we used a 
double staining method to quantify the G0 fraction.
21 The re-
duced G0 fraction seen in controls as early as 12 hours following 
release from quiescence was prevented to a large extent by CPF 
(Figure 1C). In control cells, a complete return of cell cycle distri-
bution to proliferative state was achieved at 36 hours following 
release from quiescence (all P > .05 compared with No CI and FCS). 
However, treatment with CPF caused delay in the re-entry in both 
cell lines, as the distribution of all cell cycle phases remained differ-
ent significantly from control at 36 hours (Figure 1C). No statisti-
cally significant change in cell viability was observed on treatment 
with CPF at GI90 as cell cycle analysis showed <2% cell population 
in the sub-G1 fraction.
To further validate the CPF action, we transduced A549 cells 
with mVenus-p27K− plasmid. This mutant p27 cannot bind cyclin-de-
pendent kinase but maintains an intact domain for ubiquitination. 
CPF was introduced when mVenus-p27K− cells were released from 
quiescence following 3-day contact inhibition. There was a signifi-
cant increase in fluorescent signal over the course of contact inhi-
bition compared to the proliferating cells (Figure 2A,B). The signal 
was reduced upon cell cycle re-entry. However, treatment with CPF 
at GI50 and GI90 led to a clear retention of mVenus-p27K− signal 
compared with vehicle-treated control (Figure 2C and Video). Taken 
together, these data underscore that CPF can impede cell cycle 
re-entry of quiescent lung cancer cells.
3.2 | CPF treatment decreases FACT mRNA and 
protein levels and transcriptional activity
We have shown recently that FACT is required in cell cycle re-entry 
by quiescent lung cancer cells.18 To establish the mechanism by which 
CPF impedes cell cycle re-entry, we examined the impact of CPF on 
mRNA and protein levels of FACT in cell cycle re-entry. Treatment 
with CPF efficiently reduced the surged mRNA (Figure 3A) and pro-
tein (Figure 3B, Figure S2A) levels of FACT subunit SSRP1 and SPT16 
over the time period of 6-24 hours compared with vehicle control 
cells. Moreover, consistent with our previous finding that FACT 
promotes cell cycle re-entry via p27 and its regulatory proteins in-
cluding c-MYC and SKP2,18 the CPF treatment reduced c-MYC and 
changed SKP2 and p27 over the same period (Figure 3C, Figure S2B).
To verify that the CPF-led inhibition of cell cycle re-entry is medi-
ated by reduction of FACT mRNA and protein levels, we transfected 
quiescent A549 cell line with an expression vector containing SSRP1 
or SPT16 for 4 hours after release from quiescence. At 36 hours, the 
ectopic expression of either FACT subunit significantly reduced the 
G0 fraction compared to control. While CPF alone increased the cells 
at G0 fraction compared to control, the effect of CPF on G0 fraction 
was diminished when FACT subunits were overexpressed simul-
taneously (Figure 4A, Figure S2C). Hence, CPF action on cell cycle 
re-entry could be mediated by its impact on FACT. We then used 
ChIP assays to determine the effect of CPF on H3K4 tri-methylation 
and RNA polymerase II occupancy at FACT gene promoters in A549 
cell line. There was a significant reduction of H3K4 tri-methylation 
and RNA polymerase II recruitment at SSRP1 and SPT16 gene pro-
moter regions in the presence of CPF compared with vehicle control 
(Figure 4B).
Considering that the CPF treatment reduced c-MYC almost at 
same time as FACT, we used ChIP assays to determine the occu-
pancy of H3K4 tri-methylation and RNA polymerase II at c-MYC 
gene promoter in the presence of CPF. Indeed, compared with ve-
hicle control, CPF treatment led to a significant reduction of tran-
scriptional activity at c-MYC promoter (Figure 4B) and mRNA levels 
(Figure S2D). While it is clear that FACT can regulate c-MYC in lung 
cancer cells,18 whether or not c-MYC can influence FACT expres-
sion in lung cancer cells remains unknown. Hence, we used siRNA 
to knockdown c-MYC and observed a clear decrease in SSRP1 and 
SPT16 mRNA and protein levels (Figure 4C). These data indicate the 
presence of a positive feedback loop between FACT and c-MYC ex-
pression in lung cancer cells and suggest that CPF can suppress tran-
scription of FACT and c-MYC either directly or indirectly through 
their interconnected positive loop.
3.3 | Quiescent lung cancer cells exposed to CPF 
in vitro reduced growth in vivo
Study in vivo of cell cycle re-entry by quiescent cancer cells is dif-
ficult as it is not possible to synchronize cancer cells at G0 in living or-
ganisms. Hence, A549 lung cancer cells were induced to quiescence 
by contact inhibition for 3 days. These cells were then released in 
the presence or absence of CPF at GI90 for 6 hours. While the cells 
remained at G0 based on cell cycle phase analysis, A549 cells were 
subcutaneously injected into nude mice. To demonstrate the differ-
ence between quiescent and proliferative state, the same number 
of non-synchronized A549 cells was included. The proliferative and 
quiescent cells formed measurable tumours at 3.00 ± 0.89 days and 
6.80 ± 1.33 days, respectively. The cells treated with CPF in vitro 
exhibited delayed tumour formation at 12.20 ± 1.72 days. By day 
16, the growth of proliferative cells reached an ethical end-point. In 
contrast, CPF-treated cells developed smaller tumours (Figure 5A,B) 
and were significantly lighter compared with tumours from vehicle-
treated cells. These data indicate that a 6-hour in vitro exposure of 
quiescent lung cancer cells to CPF at GI90 can reduce tumour for-
mation over 16 days mostly likely via inhibiting cell cycle re-entry as 
illustrated under in vitro condition. The same dose of CPF had no 
significant impact on normal bronchial epithelial cells (16HBE and 
BEAS-2B) in vitro (Figure 5C).
4  | DISCUSSION
The histone chaperone FACT contributes to the maintenance of a 
flexible chromatin landscape. By removing and presenting histones 
to naked DNA, FACT affects selectively nucleosome disassembly 
and assembly thereby regulating transcription and elongation of 
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a small fraction of genes.15 Hence, a therapy targeting FACT can 
influence neither globally nor on FACT only. This multitarget ap-
proach, in theory, should be beneficial considering the ability of 
cancer cells to acquire resistance to single-target therapies. FACT 
is highly expressed in poorly differentiated tumours with unfavour-
able outcome.15 Reducing expression of either FACT subunit leads 
to inhibition of proliferation and tumour cell death, probably due 
to the mechanism that FACT selectively promotes transcription of 
genes that stimulate proliferation and prohibit cell death and dif-
ferentiation.16,17 We have shown recently that FACT is necessary 
and sufficient in the switch from G0 to the proliferative state in 
lung cancer cells.18 FACT protein levels are low at G0 compared to 
the proliferating state but quickly surge upon cell cycle re-entry. 
Knockdown of FACT hindered cell cycle re-entry of quiescent cells, 
likely through a reduction in c-MYC gene expression for several 
reasons. Firstly, FACT binding at c-MYC promoter is enriched sig-
nificantly. Secondly, knockdown of either FACT subunit decreases 
c-MYC mRNA and protein levels. Thirdly, knockdown of FACT also 
reduced c-MYC target gene SKP2 mRNA and protein levels, result-
ing in an increase in G0 maintaining p27 protein levels. The present 
study has taken findings one step further by providing evidence 
that the FACT and c-MYC may form a positive loop in promoting 
each other's gene expression. We found that knockdown of c-MYC 
can decrease FACT subunit SPT16 and SSRP1 mRNA and protein 
levels. Hence, consistent with previous reports in neuroblastoma23 
and fibrosarcoma24 cell lines that FACT can be a c-MYC target 
gene, a reverse regulation of FACT by c-MYC is also present in 
lung cancer cells. Indeed, the MYC E-box transactivation motif 
can be found within ~500 base pairs upstream of transcriptional 
start sites of SPT16 and SSRP1.23 Establishing this positive loop 
is important as c-MYC is known for its critical role in regulation of 
the G0 maintenance proteins p27 and SKP2,
21,25,26 whereas FACT 
is a newly emerging player in the regulation of cell cycle re-entry.18 
Functioning as a histone chaperone protein and key transcriptional 
factor, respectively, the mutual influence of FACT and c-MYC is 
expected to be broad and well beyond each other. The positive 
loop between FACT and c-MYC can be considered as a therapeu-
tic target in preventing recurrence of lung cancer, since, despite 
the significant progress in primary treatment of lung cancer, re-
currence still occurs after the molecular targeted treatment and 
immunotherapy.27,28
While anticancer drugs such as doxorubicin, cyclophospha-
mide and cisplatin are able to target cancer cells in the non-pro-
liferating state, their genotoxicity and clinical toxicity make them 
unsuitable for long-term therapy in cancer survivors. Thus, any in-
tervention as part of post-treatment care ought to have different 
characteristics from the intensive, short-term, primary treatment. 
Based on the three selection criteria of effective therapy, minimal 
side-effect profiles and financially affordable treatment, and the 
notion of ‘old drugs for new uses’, we screened classical Chinese 
F I G U R E  2   CPF retains the mVenus-p27K- signal upon cell cycle re-entry. A, Flow cytometric analysis of mVenus fluorescence in A549 
parental cells, mVenus-p27K− without contact inhibition, and contact-inhibited mVenus-p27K−, without or with CPF upon release from 
quiescence. B, Quantification data are expressed as the mean ± SD from three experiments. *P < .05 vs No CI; #P < .05 vs RP36h CON; and 
^P < .05 vs RP36h GI50. C, Images of A549-mVenus-p27K- cells released from quiescence with or without CPF
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F I G U R E  3   CPF treatment decreases FACT mRNA and protein levels. Upon release from quiescence, A549 and H1975 cells were treated 
with CPF at GI90 for 6-24 h and then harvested for RT-qPCR (A) or immunoblotting (B) for SPT16 and SSRP1. P: proliferative cells, Q: 
quiescent cells; R: release from quiescence; C: control; and T: CPF treatment. *P < .05 vs control at same time-point. C, The quiescent cells 
were exposed to CPF at GI90 for the indicated time from releasing from quiescence and analysed for p27 and its degradation proteins by 
immunoblotting. *P < .05 vs control at same time-point
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herbal medicines from the book ‘Treatise on Miscellaneous 
Diseases’.19 CPF outcompetes others and meets the selection cri-
teria. Through physical (contact inhibition) and chemical (serum 
removal) induced quiescence and quantification of G0 fraction 
and mVenus-p27 intensity, CPF showed a clear capacity to im-
pede proliferative switch from quiescent state. The action of CPF 
is rather quick as a transcriptional reduction of FACT and c-MYC 
was noted 6 hours following administration upon release from qui-
escence. Furthermore, the impact of CPF on quiescent lung cancer 
cells appears to be relatively long-lasting, as a 6-hour exposure 
to CPF in vitro can result in reduction of tumour size and weight 
16 days following transplantation in vivo. Due to the lack of animal 
models to simulate the process of cell cycle re-entry by G0 cancer 
cells, the effect of CPF administered in living organism remains 
to be determined. To link the structure with impeding cell cycle 
re-entry action, we embarked on a process of isolating active com-
pound from CPF. Of the three components of CPF, the impeding 
cell cycle re-entry action is derived from Coptis chinensis, and not 
F I G U R E  4   CPF suppresses transcription of FACT and c-MYC genes. A, Quiescent A549 cells were transfected with either empty vector 
(control), or FACT plasmid (SPT16+ or SSRP1+), or treated with CPF at GI90, or a combination of FACT plasmid and CPF at GI90 (rescue) 
upon cell cycle re-entry for 36h. The cells were harvested for cell cycle analysis. *P < .05 vs control; B, ChIP was performed in the presence 
of CPF at GI90 or DMSO for 36 h following release from 3-day contact inhibition in A549 cells. PCR primers were designed based on FACT 
and c-MYC promoter or control region. *P < .05 vs control. C, Knockdown of c-MYC with three sets of siRNA and its impact on FACT mRNA 
and protein levels by RT-PCR, immunoblotting and quantification. *P < .05 vs NC control
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Pinellia ternata or Fructus trichosanthis. We will screen the identi-
fied 43 compounds from Coptis chinensis, and, if they are not the 
major active ingredients, we will use HPLC to obtain the fraction 
of Coptis chinensis and test each fraction in our platform of cell 
cycle re-entry. The effective fraction will be used for isolation of 
the active compound, which will then be validated by comparing 
its action and mode of action with CPF and Coptis chinensis.
The presented work also reflects our effort to use modern re-
search tools to develop a system to scientifically determine the 
efficacy of ancient Chinese medicine recipes. In 2015, the Chinese 
scientist Youyou Tu was awarded the Nobel Prize for the devel-
opment of an antimalarial drug extracted from Artemisia annua 
L.29 Realgar-Indigo naturalis receipt and its ingredients have been 
proven to be effective in treating human acute promyelocytic 
leukaemia.30 Although these are evidences of the presence of 
effective compounds in traditional Chinese medicines, for most 
Chinese medicine receipts the exact action and mode of action 
are not well defined. Since a great population is using traditional 
medicine,31 it is necessary to evaluate and validate the biomedical 
potential of Chinese medicine so that evidence can be provided 
for each recipe for its disease indication, molecular target and ac-
tive ingredients.
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